Abstract:Background Refractory system lupus erythematosus (SLE) still relies on aggressive treatment with high-dose glucocorticoids and immunosuppressive agents,but a significant proportion of patients persist with activity or relapse and show serious side-effects by the treatment.However, the imbalance of Th17 cells and regulatory T (Treg) cells in peripheral blood of patients with SLE may be an important factor in the pathogenesis of SLE.Because low-dose IL-2 can selectively enhance Treg function while avoiding the activation of effector T cells and rapamycin can promote the proliferation of Treg cells1–2,the combination of the low-dose IL-2 and rapamycin has been considered to treat refractory SLE for the purpose of remission. Objectives To observe the effect of low-dose IL-2 combined with rapamycin on the balance of Th17/Treg cells in patients with refractory SLE. Methods Eighty-two refractory SLE patients (80 women and 2 men),with a mean duration of 72.41±37.52 months and mean age of 36.22±12.48 years, were enrolled.They are in line with the standard of ACR in 1997,who are treated with glucocorticoid and immunosuppressant for more than one year, but the subjects continues to rise to a peak.After the eligible patients are given IL-2 and rapamycin in combination therapy with conventional therapy at 0, 6, 12, 24 week respectively after medication.The clinical symptoms, blood routine, urine routine, ESR, Th17 cells, Treg cells, Th17/Treg cells and the dosage of corticosteroids and immunosuppressant are registered one by one. Results At 24 week after treatment,28.9% patients with refractory SLE were relieved.Low-dose IL-2 combined with rapamycin leaded to an increase in the absolute counts of Treg cells in refractory SLE patients,from a median of 12.98 cells/ul (at week 0) to 22.1 cells/ul (at week 24) (P=0.002).The ratio of Th17/Treg cells shows a reduction from a median of 0.44 at week 0 to 0.29 at week 24 (P=0.029).No significant difference was observed in the absolute counts of Th17 after combined treatment.At week 24, the mean dosage of prednisone which refractory SLE patients were receiving decreased from 17.20 mg/d to 8.87 mg/d.And the categories of DMARDs use were also reduced (P<0.05). Conclusions Our results suggest that refractory SLE is major associated with the decreased number of Treg but not that of Th17.The Th17 and Treg cells in the peripheral blood of patients with refractory SLE tends to balance due to the significantly increase the number of Treg cells after low-dose IL-2 combined with rapamycin treatment.Low-dose IL-2 combined with rapamycin treatment can reduce the dosage of glucocorticoid and DMARDs. References Liao, W.,Lin, J. X. & Leonard,W. J.Interleukin-2 at the crossroads of effector responses,tolerance,and immunotherapy.Immunity 38,13–25 (2013). Tomasoni R, Basso V, Pilipow K, etal.Rapamycin-sensitive signals control RCR/CD28-driven Ifng,I14and Foxp3 transcription and promoter region methylation.Eur J Immunol,2011,41:2086–2096. Disclosure of Interest None declared

Rituximab As Maintenance Therapy Following Remission Induction in Relapsing or Refractory Systemic Lupus Erythematosus.

Rituximab maintenance treatment outcomes in patients with relapsing neuromyelitis optica spectrum disorder: a monocentric retrospective analysis

Multitarget Therapy For Maintenance Treatment Of Lupus Nephritis

Safety and Tolerability of Rituximab in the Treatment of Systemic Sclerosis

Rituximab as an effective add-on maintenance therapy for disease activities in childhood-onset systemic lupus erythematosus

Efficacy and safety of rituximab induction therapy and effect of rituximab maintenance for IgG4-related disease: a systematic review and meta-analysis

[Efficacy of rituximab therapy for 10 patients suffering from systemic lupus erythematosus with intestinal involvement]

Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study

Efficacy and safety of individualized rituximab in proliferative lupus nephritis

Efficacy and Safety of Rituximab Therapy for Systemic Lupus Erythematosus: a Systematic Review and Meta-Analysis

Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.

Progress of rituximab in the treatment of systemic lupus erythematosus and lupus nephritis

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort

Safety and Efficacy of Etanercept-Methotrexate Combination Therapy in Patients with Rhupus: an Observational Study of Non-glucocorticoid Treatment for Rheumatic Diseases

The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis

Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up

A Prospective Cohort Study of Rituximab in the Treatment of Refractory Nephrotic Syndrome

SAT0261 Refractory Systemic Lupus Erythematosus is Mainly Associated with the Decreased Number of Regulatory T Cells and Low-Dose Il-2 Combined with Rapamycin Can Efficiently Recovery the Balance of Th17/regulatory T Cells

Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy

Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection